Cancer drugs in US are ‘not affordable,’ says German study, which suggests setting drug prices by indication 

US pol­i­cy­mak­ers and pay­ers should con­sid­er in­di­ca­tion-based pric­ing in a bid to cut down on high­er can­cer drug costs in the US, ac­cord­ing to re­search re­cent­ly pub­lished by two Ger­man on­col­o­gists.

The study, pub­lished last month, looked at how can­cer drugs ap­proved for mul­ti­ple in­di­ca­tions are priced in the US.

“New can­cer drugs are not af­ford­able in the Unit­ed States,” the au­thors wrote, af­ter an­a­lyz­ing 145 FDA-ap­proved can­cer drugs with 373 to­tal in­di­ca­tions. Can­cer drugs cost an av­er­age of $24,000 a month and have a me­di­an month­ly price of $16,000. More than 95% of these drugs cost more than $10,000 a month.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.